Mission Statement, Vision, & Core Values (2026) of Tianjin Chase Sun Pharmaceutical Co.,Ltd.

Rooted in Tianjin since its founding in 1996, Tianjin Chase Sun Pharmaceutical Co., Ltd. has grown into a high-tech health group with over 5,400 employees and total assets of RMB 6.4 billion (early 2016), uniting Chinese herbal preparations, medicinal granules, synthetic and biotech drugs, medical apparatus and internet-based therapies under a single industrial cluster; driven by a mission to 'persevere, committed to enhancing people's healthy living quality,' Chase Sun channels innovation-allocating 10% of annual sales to R&D and offering equity incentives to 70 key researchers-while planning to expand core talent to 800-1,000 by 2020, and pursues a vision as 'the inheritor of Chinese medicine and the leader of health industry' through infrastructure like Tianjin's first technology transformation center and academician workstation and proprietary products such as Xuebijing injection and Full Composition formula granules; its core values - Innovation, Integrity, Cooperation, Inclusiveness and Responsibility - are measured by concrete outcomes: a 15% rise in R&D investment in 2023 yielding three new pharmaceuticals, a 95% participation rate in compliance training, formation of an Innovation Alliance with research partners, a 25% reduction in carbon emissions year-over-year, and a 98% quality assurance audit rating in 2023, all signaling why the company's strategic mission, vision and values merit a closer look

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ) - Intro

• Founded: 1996
• Headquarters: Tianjin, China
• Stock code: 300026.SZ
• Employees: >5,400 (as of early 2016)
• Total assets: RMB 6.4 billion (early 2016)

• Develop and deliver safe, effective pharmaceutical and health products rooted in both modern biotechnology and traditional Chinese medicine.
• Integrate full‑chain capabilities-from raw material cultivation to innovative internet‑based therapy-to improve patient access and outcomes.
• Create long‑term shareholder value through R&D‑led growth, operational efficiency and strategic capital deployment.

• Become a leading integrated pharmaceutical and health group combining TCM heritage with modern drug development and digital health solutions.
• Scale domestic and international presence through diversified product pipelines, manufacturing excellence and platform‑based healthcare services.

• Patient‑first: Prioritize safety, efficacy and accessibility in product development and service delivery.
• Innovation: Invest in R&D across chemical, biological and digital therapeutics to sustain competitive advantage.
• Integrity: Maintain regulatory compliance, quality management and transparent corporate governance.
• Collaboration: Build industry clusters and partnerships spanning cultivation, manufacturing, clinical research and distribution.
• Sustainability: Emphasize responsible sourcing of herbal materials and long‑term stewardship of manufacturing and environmental practices.

• R&D investment concentration on biotech and TCM modernization (targeted pipeline advancement and IND/CTA filings).
• Capacity expansion across GMP facilities and TCM granule production to support domestic hospital & retail channels.
• Digital health integration-develop internet‑based therapy solutions and wearable medical devices to capture end‑to‑end patient engagement.

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ) - Overview

Mission: 'Persevere, committed to enhancing people's healthy living quality.'

• Allocate 10% of annual sales revenue to research and development to support innovation teams and attract senior talent.
• Implemented an equity incentive plan covering 70 key scientific research members to stimulate creativity and retention.
• Targeted talent expansion: by 2020 planned to double the size of its talent pool, increasing core members to between 800 and 1,000.
• Prioritize technical innovation and strengthening R&D capabilities to improve healthcare quality of life.
• Alignment with vision: become 'the inheritor of Chinese medicine and the leader of health industry,' integrating traditional Chinese medicine (TCM) with modern healthcare solutions.

Core values and cultural pillars:

• Patient-first responsibility - health impact as primary KPI.
• Innovation-driven growth - sustained investment in R&D and talent incentives.
• Integrity and compliance - adherence to regulatory standards and ethical research.
• Collaboration and knowledge sharing - cross-disciplinary teams to bridge TCM and modern medicine.
• Long-term stewardship - balancing commercial performance with public health outcomes.

Operational levers translating mission into measurable action:

• R&D spending policy: commit 10% of sales to fund discovery, clinical development, and platform technology.
• Talent programs: equity incentives for top 70 researchers plus accelerated hiring to reach 800-1,000 core members.
• Pipeline acceleration: prioritize projects with clear QOL (quality of life) endpoints and TCM-modern integration.
• Partnerships and acquisitions: scout complementary assets to broaden therapeutic reach and manufacturing capacity.

For investor context and deeper profile information: Exploring Tianjin Chase Sun Pharmaceutical Co.,Ltd Investor Profile: Who's Buying and Why?

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ) - Mission Statement

• Mission focus: preserve and modernize TCM while delivering evidence-based therapies and health solutions to improve quality of life.
• Strategic pillars: R&D-driven innovation, IP ownership, industrial-scale manufacturing, and healthcare ecosystem leadership.
• Operational priorities: strengthen clinical validation, expand granularized formula platforms, and scale market access domestically and internationally.

• The vision drives continued investment in technology platforms and clinical evidence generation for TCM products.
• It shapes product strategy: focus on proprietary injections, granules, and integrated health solutions with independent intellectual property rights.
• Institutional commitments such as the Tianjin technology transformation center and an academician workstation anchor the company's leadership claim.

• Xuebijing injection - an established proprietary product with wide clinical adoption in China for systemic inflammatory conditions and sepsis adjunct therapy.
• Full Composition formula granules - platform for standardized, granulated TCM formulas enabling scalable clinical dosing and GMP manufacturing.
• Independent intellectual property portfolio spanning formulation patents, process patents, and quality control technologies.

• Product strategy aligns with vision: focus on IP-backed TCM injections and standardized granules to raise clinical credibility and global scalability.
• Manufacturing and technology centers underpin quality and scale, enabling compliance with GMP and export standards.
• Clinical and academic partnerships (academician workstation) accelerate evidence generation and enhance medical community adoption.

• Clinical trials and hospital partnerships to expand evidence base for proprietary TCM injections (boosting clinical uptake and guideline inclusion).
• Scaling granularized formula production to meet demand in hospitals, clinics, and consumer health channels.
• Continuous modernization of manufacturing lines through the Tianjin technology transformation center to ensure quality, yield, and regulatory compliance.

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ) - Vision Statement

• Innovation: continuous investment in R&D to drive therapeutic breakthroughs and pipeline growth.
• Integrity: uncompromising adherence to ethical standards and regulatory compliance.
• Cooperation: open collaboration with industry and research partners to accelerate translation of science to medicine.
• Inclusiveness: commitment to sustainability and broad stakeholder engagement.
• Responsibility: delivering high-quality products and accountable corporate citizenship.

• R&D investment: a 15% increase in 2023, enabling the development and launch of three new pharmaceutical products during the year.
• Compliance & ethics: company-wide compliance training achieved a 95% participation rate in 2023, reinforcing integrity across functions.
• Collaborative ecosystem: establishment of the Innovation Alliance with enterprises as the core, fostering ongoing partnerships with scientific research institutions.
• Environmental performance: achieved a 25% reduction in carbon emissions in 2023 versus 2022, reflecting commitments under inclusiveness and sustainability.
• Quality assurance: attained a 98% rating in quality assurance audits conducted in 2023, underpinning responsibility for product safety and efficacy.

• Scale R&D: prioritize therapeutic areas with high unmet need and allocate incremental budget to translational programs and clinical development.
• Strengthen compliance: maintain and expand training and monitoring systems to preserve the 95%+ engagement and continuous regulatory alignment.
• Deepen partnerships: grow the Innovation Alliance network to accelerate access to external expertise and co-development opportunities.
• Accelerate sustainability: continue initiatives that delivered a 25% emissions reduction, with measurable short- and medium-term targets.
• Ensure quality excellence: institutionalize processes that sustain or improve the 98% quality audit rating across manufacturing and supply chain.